A Non-Pharmacological Method for Enhancing Sleep in PTSD
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT02370173|
Recruitment Status : Recruiting
First Posted : February 24, 2015
Last Update Posted : October 8, 2019
Sleep disturbance is nearly ubiquitous among individuals suffering from PTSD and is a major problem among service members returning from combat deployments. The proposed study aims to test a novel, inexpensive, and easy to use approach to improving sleep among service members with PTSD.
Primary outcome measures will include not only PTSD symptom improvement but also include neuroimaging of brain structure, function, connectivity, and neurochemistry changes. The proposal is firmly grounded in the emerging scientific literature regarding sleep, light exposure, brain function, anxiety, and resilience. Prior evidence suggests that bright light therapy is effective for improving mood and fatigue, and our pilot data further suggest that this treatment may be effective for improving daytime sleepiness and brain functioning in brain injured individuals. Thus, this intervention, in our own research and in the work of others, has been shown to affect critical sleep regulatory systems. Improving sleep may be a vital component of recovery in these service members. Our approach would directly address this issue. Our preliminary data have shown that this approach is extremely well tolerated and is effective for improving sleep, mood, cognitive performance, and brain function among individuals with brain injuries.
Finally, the potential impact of this study is high because of the capability of transitioning the research to direct clinical application almost immediately. If the bright light treatment is demonstrated as effective, this approach would be readily available for nearly immediate large-scale implementation, as the devices have been widely used for years in other contexts, are already safety tested, and commercially available from several manufacturers for a very low cost. Thus, the impact of this research on treating PTSD would be high and immediate.
|Condition or disease||Intervention/treatment||Phase|
|PTSD Sleep Problems||Device: PTSD wavelength-1 bright light Device: PTSD wavelength-2 bright light||Not Applicable|
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||90 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||Double (Participant, Outcomes Assessor)|
|Official Title:||A Non-Pharmacological Method for Enhancing Sleep in PTSD|
|Study Start Date :||September 2014|
|Estimated Primary Completion Date :||September 2020|
|Estimated Study Completion Date :||December 2020|
Experimental: PTSD wavelength-1 bright light
30 minutes of daily light exposure for 6 weeks
Device: PTSD wavelength-1 bright light
6 weeks of daily light exposure, 30 minutes per morning.
Placebo Comparator: PTSD wavelength-2 bright light
30 minutes of daily light exposure for 6 weeks
Device: PTSD wavelength-2 bright light
6 weeks daily light exposure, 30 minutes per morning.
- Sleep Quality [ Time Frame: Change from baseline at 6 weeks (post-treatment) ]The Subjective Measure: Pittsburgh Sleep Quality Index and Objective measure: Actigraphy, will be used to assess average sleep quality.
- Neural activation during functional magnetic resonance imaging (fMRI) executive function task [ Time Frame: Change from baseline performance at 6 weeks (post-treatment) ]
- Performance on neuropsychological assessment [ Time Frame: Change from baseline performance at 6 weeks (post-treatment) ]The Automated Neuropsychiatric Assessment Metrics and the Repeatable Battery for the Assessment of Neuropsychological Status will be utilized to measure overall neurocognitive performance.
- PTSD Symptoms [ Time Frame: Change from baseline performance at 6 weeks (post-treatment) ]The PTSD Checklist will be used to measure PTSD symptoms.
- Daytime Sleepiness [ Time Frame: Change from baseline performance at 6 weeks (post-treatment) ]Subjective measures: Epworth Sleepiness Scale, and Stanford sleepiness Scale, and the Objective measure: Multiple Sleep Latency Test (MSLT) will be used to assess daytime sleepiness.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02370173
|Contact: Meltem Ozcanfirstname.lastname@example.org|
|Contact: Caleigh Shepardemail@example.com|
|United States, Arizona|
|University of Arizona||Recruiting|
|Tucson, Arizona, United States, 85724|
|Contact: Meltem Ozcan firstname.lastname@example.org|
|Principal Investigator: William Killgore, Ph.D.|
|Principal Investigator:||William Killgore, Ph.D.||University of Arizona|